Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Nikolai Siebert"'
Autor:
Hannes Forkel, Piotr Grabarczyk, Maren Depke, Sascha Troschke-Meurer, Stefan Simm, Elke Hammer, Stephan Michalik, Christian Hentschker, Björn Corleis, Lucie Loyal, Maxi Zumpe, Nikolai Siebert, Anca Dorhoi, Andreas Thiel, Holger Lode, Uwe Völker, Christian A. Schmidt
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
ABSTRACTBCL11B, an essential transcription factor for thymopoiesis, regulates also vital processes in post-thymic lymphocytes. Increased expression of BCL11B was recently correlated with the maturation of NK cells, whereas reduced BCL11B levels were
Externí odkaz:
https://doaj.org/article/38c9a1f16c6741208dbf26b7a38a18f3
Autor:
Wolfgang Glienke, Anna Christina Dragon, Katharina Zimmermann, Alexandra Martyniszyn-Eiben, Mira Mertens, Hinrich Abken, Claudia Rossig, Bianca Altvater, Krasimira Aleksandrova, Lubomir Arseniev, Christina Kloth, Andriana Stamopoulou, Thomas Moritz, Holger N. Lode, Nikolai Siebert, Rainer Blasczyk, Lilia Goudeva, Axel Schambach, Ulrike Köhl, Britta Eiz-Vesper, Ruth Esser
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus, approaches using 4th advanced CAR T cells secreting immunomodulatory cy
Externí odkaz:
https://doaj.org/article/0a0e47512e424a90ba1c2e5115780b13
Autor:
Christian Martin Seitz, Tim Flaadt, Markus Mezger, Anne-Marie Lang, Sebastian Michaelis, Marie Katz, Desireé Syring, Alexander Joechner, Armin Rabsteyn, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Holger N. Lode, Sile F. Yang, Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Florian Heubach, Rupert Handgretinger, Peter Lang, Patrick Schlegel
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Haploidentical stem cell transplantation (haplo SCT) in Stage IV neuroblastoma relapsed patients has been proven efficacious, while immunotherapy utilizing the anti-GD2 antibody dinutuximab beta has become a standard treatment for neuroblastoma. The
Externí odkaz:
https://doaj.org/article/3db6c45432c649c5ab96cdd2344832c5
Autor:
Filiz Cicek, Sascha Troschke-Meurer, Kiraz Ceylan, Luciana J. Jahns, Maxi Zumpe, Nikolai Siebert, Karoline Ehlert, Holger N. Lode
Publikováno v:
Frontiers in Pediatrics, Vol 8 (2020)
Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninet
Externí odkaz:
https://doaj.org/article/d64eecd9b1d8462d88e41db19379f01a
Autor:
Holger Lode, Nikolai Siebert, Karoline Ehlert, Ina Hansjuergens, Andreas Zinke, Sylke Otto, Guenter Henze
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Neuroblastoma (NB) is the most frequent extracranial solid tumor in children. More than 50% of patients present with widespread (stage M) or refractory disease. In these patients, event-free and overall survival was improved by the additio
Externí odkaz:
https://doaj.org/article/4491a5af76954b53a40f9361fda9e21c
Autor:
Nikolai Siebert, Maxi Zumpe, Leon von Lojewski, Sascha Troschke-Meurer, Madlen Marx, Holger N. Lode
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Neuroblastoma (NB) still remains a major challenge in pediatric oncology. We recently showed CD11b+-dependent upregulation of the PD-1/PD-L1 checkpoint on NB cells treated with the chimeric anti-GD2 antibody (Ab) ch14.18/CHO. Here, we report effects
Externí odkaz:
https://doaj.org/article/c4972936abb24748a9d0e6ea4e1fdc35
Autor:
Sascha Troschke-Meurer, Nikolai Siebert, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Oliver Mutschlechner, Hans Loibner, Ruth Ladenstein, Holger N. Lode
Publikováno v:
OncoImmunology, Vol 8, Iss 12 (2019)
Immunotherapy with the anti-GD2 antibody (Ab) ch14.18/CHO in combination with interleukin 2 (IL-2) has improved survival of high-risk neuroblastoma (NB) patients. Here, we report immunotherapy-related effects on circulating NK cells, regulatory T cel
Externí odkaz:
https://doaj.org/article/1add2821f0c7408d98e60669870206e0
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207320 (2018)
Long-term survival of high-risk neuroblastoma (NB) patients still remains under 50%. Here, we report the generation, in vitro characterization and anti-tumor effectivity of a new bicistronic xenogenic DNA vaccine encoding tyrosine hydroxylase (TH) th
Externí odkaz:
https://doaj.org/article/771ff7bb02fe407bac8835a05403efbe
Publikováno v:
OncoImmunology, Vol 6, Iss 10 (2017)
Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC). Strategies to further enhance the efficacy are im
Externí odkaz:
https://doaj.org/article/80b8c37353e54ee095987490da130f1e
Autor:
Christin Eger, Nikolai Siebert, Diana Seidel, Maxi Zumpe, Madlen Jüttner, Sven Brandt, Hans-Peter Müller, Holger N Lode
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150479 (2016)
Vaccination with proteins mimicking GD2 that is highly expressed on neuroblastoma (NB) cells is a promising strategy in treatment of NB, a pediatric malignancy with poor prognosis. We previously showed efficacy of ganglidiomab in vivo, a murine anti-
Externí odkaz:
https://doaj.org/article/722b8a4462904a83ba30b2249f8e773d